Cornell researchers have developed a new vaccine platform that could provide more robust, longer-lasting protection from both ...

Vaccines are one of, if not the, most important developments in public health history, and despite nearly a century of data, ...

Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Novavax Inc. (NVAX) shares climbed over 1% in after-hours trading Thursday as the vaccine maker's revenue outlook and ...

Novavax said it was eligible to receive royalties in high teens to low twenties percent on Sanofi sales, up to $350 million ...

During the quarter, GSK did not record any sales from the COVID-19 booster vaccine, which was co-developed with Sanofi SNY. Core selling, general and administration (SG&A) costs rose 6% to £2.70 ...

But there have been plenty of other illnesses to go around. By Francesca Paris This winter’s Covid wave in the United States has been the gentlest to date, in a welcome reprieve. Source ...

L’Oreal OR0.83%increase; green up pointing triangle will sell part of its stake in Sanofi SAN-0.46%decrease; red down pointing triangle back to the French pharmaceutical company for 3 billion ...

© 2025 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...

Higher levels of long COVID were found in lower-income households. More than 1 million children may have been affected by long COVID as of 2023, new federal data published Monday suggests.

Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L'Oréal, the first of multiple share buybacks the French drugmaker has planned for 2025. L'Oréal was selling 29,556,650 ...